òòò½Íø

Biologics Pharma Innovation Programme òòò½Íø(BioPIPS)

BioPIPS or the Biologics Pharma Innovation Programme òòò½Íøaims to strengthen local biomanufacturing capabilities and transform Singapore’s biologics manufacturing facilities into agile factories of the future. It works through a consortium model consisting leading biopharma companies and Singapore’s public sector R&D agencies and universities. BioPIPS is modelled after PIPS.

Vision: Transform biologics manufacturing through the introduction of new technologies and products into Singapore’s manufacturing facilities. 

Objectives:

  • Leverage public sector R&D capabilities to address problem statements from local biologics manufacturing facilities to enhance manufacturing productivity and operational efficiency 
  • Transform the existing biologics manufacturing operations in òòò½Íøso that the manufacturing sites are best-in-class within their respective manufacturing network and well positioned for the introduction of new products and novel manufacturing technologies
  • Leverage strong foundation through synergies in operations, resources, learning and collaboration of technologies with PIPS
BioPIPS intro

Consortium Members

Combined Consortium Logos BioPIPS

A consortium agreement was inked on 15 March 2024 between the òòò½Íø, Technology and Research (A*STAR), National University of òòò½Íø(NUS), Nanyang Technological University, òòò½Íø(NTU Singapore), òòò½ÍøInstitute of Technology (SIT) and 3 major pharmaceutical MNCs, i.e. ,  and . They are also the founding Core Members of BioPIPS.

The Extended Team is a diverse group consisting pharmaceutical supply chain, technology, consultancy, training and engineering companies, including SMEs and LLEs invited by the Core Members to participate in specific projects. Interested companies are encouraged to contact the BioPIPS Programme Office to find out more about joining the consortium.

Note: Companies are listed in alphabetical order.


Signing Ceremony BioPIPS (800px)
BioNTech, GSK, Sanofi, NTU, NTUitive, NUS and SIT signed a membership agreement on 15 March 2024 to join the Biologics Pharma Innovation Programme òòò½Íø(BioPIPS) consortium led by A*STAR and supported by EDB. EDB’s Cindy Koh, Executive Vice President and Member of EXCO, witnessed the membership agreement signing.

Workstreams

Sensing and Modelling
Focuses on developing and validating in-process, automated workflows to translate process performance into actionable knowledge. Specifically, the aim is to improve the accuracy and robustness of sensing technologies and facilitate the incorporation of AI and modelling approaches into manufacturing processes to enable quicker and more effective product and process control.
Sensing and Modelling (600px x 400px)

Sustainability
Focuses on technologies to achieve sustainability targets, including zero waste-to-landfill, and reducing environmental footprint and greenhouse gas emissions. The workstream aims to use models to identify sustainability bottlenecks in manufacturing and supply chains, explore new technologies to reduce resource utilisation and waste generation, and rethink the expanded utility of single-use equipment through the lens of materials science and circular economy considerations.
sustainable-(600px x 400px)

Compliant Agility
Underpinning medicine supply is the trust in the efficacy and safety of the manufactured products which need to comply to regulations. This workstream focuses on removing manual tasks to achieve greater productivity in the manufacturing facilities while maintaining compliance by using solutions, e.g. robotics, automation and advanced analytics. 
biorobots-concept (600px x 400px)

Application Materials for Grant Call

Biologics Pharma Innovation Programme òòò½Íø(BioPIPS) Grant Call 3 - Sensing and Modelling, and Sustainability has opened for submission on 3 March 2025.

Submission Deadline for Full Proposals: 11 April 2025, 12.00 pm (SGT)
Full proposals must be submitted to biopips@bti.a-star.edu.sg using the template provided.

Media Releases

BioPIPS consortium in òòò½Íøexpands membership, seeks to enhance productivity and sustainability in biologics manufacturing, A*STAR Press Release
18-Mar-2024

SINGAPORE – The Biologics Pharma Innovation Programme òòò½Íø(BioPIPS) has been expanded with the addition of global immunotherapy company, i.e. BioNTech Pharmaceuticals Asia Pacific Pte Ltd. The company joins global pharmaceutical companies, i.e. GSK and Sanofi, alongside Singapore’s research organisations and Institutes of Higher Learning, i.e. òòò½Íø, Technology and Research (A*STAR), Nanyang Technological University, òòò½Íø(NTU Singapore) and its innovation and enterprise company, i.e. NTUitive, National University of òòò½Íø(NUS) and òòò½ÍøInstitute of Technology (SIT).

The consortium is led by A*STAR and supported by the Economic Development Board (EDB). It aims to grow Singapore’s capabilities in biologics manufacturing by focusing on increasing productivity and sustainability to transform the existing base of biologics production in Singapore.


Get in touch with BioPIPS

Biologics Pharma Innovation Programme òòò½Íø(BioPIPS) Programme Office
31 Biopolis Way
#08-01 Nanos
òòò½Íø138669

For all enquiries, contact us at biopips@bti.a-star.edu.sg. We will get back to you as soon as we can.


Connect with us

A*STAR celebrates International Women's Day

A*STAR Women In Science

From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.